Get the Stockscreener App
23.07
2.53%
0.57
Septerna Inc stock is traded at $23.07, with a volume of 14,635.
It is up +2.53% in the last 24 hours and up +0.00% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
See More
Previous Close:
$22.50
Open:
$22.76
24h Volume:
14,635
Relative Volume:
0.27
Market Cap:
$999.06M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.08%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$22.40
$23.30
1-Week Range:
$21.45
$25.32
52-Week Range:
$18.62
$26.34
Septerna Inc Stock (SEPN) Company Profile
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SEPN | 23.04 | 999.06M | 0 | 0 | 0 | 0.00 |
| VRTX | 448.33 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.13 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.33 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Septerna Inc Stock (SEPN) Latest News
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
JPMorgan Chase & Co. Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna, Inc. Reports Q3 2024 Financials and Progress - TipRanks
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Septerna initiated with an Overweight at JPMorgan - Yahoo Finance
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Australia
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Now Covered by Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
JPMorgan Chase & Co. Initiates Coverage on Septerna (NASDAQ:SEPN) - MarketBeat
Wells Fargo & Company Initiates Coverage on Septerna (NASDAQ:SEPN) - MarketBeat
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com UK
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering - ForexTV.com
Ra Capital Management buys $75 million in Septerna stock By Investing.com - Investing.com Australia
Ra Capital Management buys $75 million in Septerna stock - Investing.com
IPO Radar: Septerna, Swiggy and Horizon Robotics - The Armchair Trader
Septerna sees $11.7 million in stock purchases by Third Rock Ventures - Investing.com South Africa
IPO Roundup: Brazil Potash, Septerna and more (NYSEARCA:IPO) - Seeking Alpha
Septerna proposes terms for upsized $175M IPO - MSN
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Septerna’s GPCRs draw strong demand in $288M IPO - BioCentury
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Hedge Funds, Asset Managers Turn Dollar Bulls on Election Risks - Yahoo Finance
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Septerna Shares Rise 29% on First Trading Day - MarketWatch
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - MedCity News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut - KFGO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot - AllSides
Goodwin, Cooley Guide Septerna's Upsized $288M IPO - Law360
Septerna's $288M IPO is another sign of the market warming to biotech investment - Fierce Biotech
Septerna Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Septerna Rings the Opening Bell - Nasdaq
MicroStrategy Touches New Highs as Trading Volume Relative to Nvidia Surges - Yahoo Finance
Septerna Prices Upsized 16M Share IPO at $18/sh By Investing.com - Investing.com Nigeria
Septerna Prices Upsized 16M Share IPO at $18/sh - Investing.com
Septerna Shares Set for Trading Debut After Upsized IPO - MarketWatch
Goldman-backed drug developer Septerna raises $288mln in US IPO - ZAWYA
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):